Peringkat dalam Saham
#28207
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based... Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Harga Saham
$0.4
Terakhir disinkronkan: 2026-10-02
Kapitalisasi Pasar
$27.18M
Perubahan (1 hari)
-14.88%
Perubahan (1 tahun)
8.11%
Perdagangan Cell Source, Inc. (CLCS)
Harga CLCS dengan kapitalisasi pasar B
Kapitalisasi pasar dari Cell Source, Inc.(CLCS)
Kapitalisasi Pasar: $27.18M
Per October 2026, Cell Source, Inc. memiliki kapitalisasi pasar sebesar $27.18M. Ini menjadikan Cell Source, Inc. sebagai perusahaan 28207th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Cell Source, Inc. dari 2014 hingga 2026
CLCS dibandingkan dengan 5 teratas stocks paling populer
| Harga CLCS |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.807T
|
+21,367,012.68%
|
|
|
|
|
$4.891T
|
+17,994,900.12%
|
|
|
|
|
$4.177T
|
+15,369,855.18%
|
|
|
|
|
$3.919T
|
+14,417,670.59%
|
|
|
|
|
$2.724T
|
+10,022,661.63%
|
